References
1. World Health Organization, Coronavirus disease 2019 (COVID-19): situation report, 121. 2020. P. 19.
2. Madjid M., et al. Potential effects of coronaviruses on the cardiovascular system: a review. JAMA Cardiol. 2020 Mar 27.
3. Russian Society of Cardiology. Guidelines for the diagnosis and treatment of circulatory diseases in the context of the COVID-19 pandemic. Rossiyskiy kardiologicheskiy zhurnal [Russian Journal of Cardiology]. 2020: 25 (3): 1-20. (in Russian)
4. Zadori N., et al. The negative impact of comorbidities on the disease course of COVID-19. Intensive Care Med. 2020: 1-3.
5. Gopinathannair R., et al. COVID-19 and cardiac arrhythmias: a global perspective on arrhythmia characteristics and management strategies. J Interv Card Electrophysiol. 2020: 1-8.
6. Liu K., et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J (Engl). 2020; 133 (9): 1025-31.
7. Guo T., et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020 Mar.
8. Shi S., et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020; 5 (7): 802-10.
9. Al Jaroudi W.A., Hage F.G. Cardiovascular disease in the literature: a selection of recent original research papers. J Nucl Cardiol. 2020; 27 (3): 712-4.
10. Tersalvi G., et al. Elevated troponin in patients with coronavirus disease 2019: possible mechanism. J Card Fail. 2020; 26 (6): 470-5.
11. Mahajan K., Chandra K.S. Cardiovascular comorbidities and complications associated with corona-virus disease 2019. Med J Armed Forces India. 2020 May.
12. Babapoor-Farrokhran S., et al. Myocardial injury and COVID-19: possible mechanisms. Life Sci. 2020; 253: 117723.
13. Driggin E., et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J Am Coll Cardiol. 2020; 75 (18): 2352-71.
14. Iba T., et al. The unique characteristics of CO-VID-19 coagulopathy. Crit Care. 2020; 24 (1): 360.
15. Huang C., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395 (10 223): 497-506.
16. Zhou F., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395 (10 229): 1054-62.
17. Lippi G., Lavie C.J., Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (CO-VID-19): evidence from a meta-analysis. Prog Cardiovasc. Dis. 2020 Mar.
18. Krittanawong C., et al. Coronavirus disease 2019 (COVID-19) and cardiovascular risk: a meta-analysis. Prog Cardiovasc Dis. 2020; 63 (3): 390-1.
19. Gao L., et al. Prognostic value of NT-proBNP in patients with severe COVID-19. Respir Res. 2020; 21 (1): 83.
20. Smirnov V.P., Panysheva I.A. Cardiomyocyte pathomorphology in sudden cardiac death. In: Medicine: challenges of today: materials of the III International scientific conference. Moscow: Buki-Vedi, 2016: 43-6. (in Russian)
21. Kochi A.N., et al. Cardiac and arrhythmic complications in patients with COVID-19. J Cardiovasc Electrophysiol. 2020; 31 (5): 1003-8.
22. Marijon E., et al. Out-of-hospital cardiac arrest during the COVID-19 pandemic in Paris, France: a population-based, observational study. Lancet Public Health. 2020; 5 (8): e437-43.